The valiant effort to develop mRNA-based vaccines against pandemic coronavirus was not only successful but safe and efficacious vaccines were achieved in record time. While the analytical tools used to verify the critical quality attributes (CQA) of mRNA vaccines played a vital role in that success, there is a widely acknowledged need for more cost and labor-efficient methods. Furthermore, developing the new generation of multivalent mRNA vaccines poses additional challenges. The multiplexed VaxArray Platform is ideally suited to address the need for rapid and accurate verification of the identity, quantity, and stability of mRNA vaccines and therapeutics, including multivalent drug products.

In this GEN webinar, our distinguished guest, Dr. Kathy Rowlen, will detail the performance characteristics of a VaxArray Assay for multivalent influenza mRNA formulations that include constructs for both hemagglutinin and neuraminidase. Dr. Rowlen will also show us data demonstrating assay specificity, sensitivity, accuracy, and precision for both “naked” and lipid-encapsulated mRNA. In addition, the total assay time is less than 2 hours, with no need for deformulation or extraction, resulting in the desired cost and speed efficiency for mRNA CQA testing.

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.